1. Home
  2. MOS vs DVA Comparison

MOS vs DVA Comparison

Compare MOS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mosaic Company (The)

MOS

Mosaic Company (The)

HOLD

Current Price

$24.50

Market Cap

8.3B

Sector

Industrials

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$119.98

Market Cap

9.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOS
DVA
Founded
1987
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Misc Health and Biotechnology Services
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
9.4B
IPO Year
2004
1995

Fundamental Metrics

Financial Performance
Metric
MOS
DVA
Price
$24.50
$119.98
Analyst Decision
Buy
Hold
Analyst Count
14
4
Target Price
$34.93
$145.00
AVG Volume (30 Days)
8.0M
1.1M
Earning Date
11-04-2025
10-29-2025
Dividend Yield
3.59%
N/A
EPS Growth
235.95
5.63
EPS
3.87
9.76
Revenue
$11,894,600,000.00
$13,317,965,000.00
Revenue This Year
$16.57
$6.24
Revenue Next Year
$1.03
$3.32
P/E Ratio
$6.34
$12.26
Revenue Growth
3.83
5.14
52 Week Low
$22.36
$113.97
52 Week High
$38.23
$179.60

Technical Indicators

Market Signals
Indicator
MOS
DVA
Relative Strength Index (RSI) 34.69 45.71
Support Level $23.35 $113.97
Resistance Level $24.42 $122.16
Average True Range (ATR) 0.70 2.98
MACD 0.14 0.40
Stochastic Oscillator 38.89 50.98

Price Performance

Historical Comparison
MOS
DVA

About MOS Mosaic Company (The)

Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida and Peru and potash mines in Saskatchewan and New Mexico. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Share on Social Networks: